Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyuki Hata

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
Cancer Research|June 5, 2007
Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growthHiro Tatetsu, Shikiko Ueno, Hiroyuki Hata, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 12, 2010
Excessive fibrinolysis in AL-amyloidosis is induced by urokinae-type plasminogen activator from bone marrow plasma cellsMitsuhiro Uchiba, Takahisa Imamura, Hiroyuki Hata, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|November 8, 2019
[Spontaneous remission of acquired factor XIII inhibitor concurrent to development of IgA-λ type multiple myeloma]Shikiko Ueno, Junko Nozaki, Shinichi Kusano, et al.
International Journal of Hematology|July 9, 2013
Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 studyYasushi Takamatsu, Kazutaka Sunami, Tsuyoshi Muta, et al.
International Journal of Hematology|September 9, 2010
A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myelomaYasushi Takamatsu, Kazutaka Sunami, Hiroyuki Hata, et al.
Leukemia & Lymphoma|January 7, 2006
Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cellsMiki Nakamura, Tomomi Gotoh, Yutaka Okuno, et al.
Journal of Microbiological Methods|June 23, 2019
Evaluation of Q Gene Mycobacteria: A novel and easy nucleic acid chromatography method for mycobacterial species identificationKinuyo Chikamatsu, Akio Aono, Akiko Kawai, et al.
Oncology Reports|October 14, 2011
TRAIL produced from multiple myeloma cells is associated with osteolytic markersYawara Kawano, Shikiko Ueno, Masahiro Abe, et al.
International Journal of Oncology|September 25, 2008
Induction of cell cycle arrest and apoptosis in myeloma cells by cepharanthine, a biscoclaurine alkaloidYoshitaka Kikukawa, Yutaka Okuno, Hiro Tatetsu, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|October 23, 2015
Successful Treatment of Bing-Neel Syndrome Accompanying Waldenström's Macroglobulinemia with R-MPV: A Case ReportYoshitaka Kikukawa, Ayako Yamamura-Fujimoto, Shinya Endo, et al.
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Cancer Research|June 5, 2007
Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growthHiro Tatetsu, Shikiko Ueno, Hiroyuki Hata, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 12, 2010
Excessive fibrinolysis in AL-amyloidosis is induced by urokinae-type plasminogen activator from bone marrow plasma cellsMitsuhiro Uchiba, Takahisa Imamura, Hiroyuki Hata, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|November 8, 2019
[Spontaneous remission of acquired factor XIII inhibitor concurrent to development of IgA-λ type multiple myeloma]Shikiko Ueno, Junko Nozaki, Shinichi Kusano, et al.
International Journal of Hematology|July 9, 2013
Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 studyYasushi Takamatsu, Kazutaka Sunami, Tsuyoshi Muta, et al.
International Journal of Hematology|September 9, 2010
A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myelomaYasushi Takamatsu, Kazutaka Sunami, Hiroyuki Hata, et al.
Leukemia & Lymphoma|January 7, 2006
Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cellsMiki Nakamura, Tomomi Gotoh, Yutaka Okuno, et al.
Journal of Microbiological Methods|June 23, 2019
Evaluation of Q Gene Mycobacteria: A novel and easy nucleic acid chromatography method for mycobacterial species identificationKinuyo Chikamatsu, Akio Aono, Akiko Kawai, et al.
Oncology Reports|October 14, 2011
TRAIL produced from multiple myeloma cells is associated with osteolytic markersYawara Kawano, Shikiko Ueno, Masahiro Abe, et al.
International Journal of Oncology|September 25, 2008
Induction of cell cycle arrest and apoptosis in myeloma cells by cepharanthine, a biscoclaurine alkaloidYoshitaka Kikukawa, Yutaka Okuno, Hiro Tatetsu, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|October 23, 2015
Successful Treatment of Bing-Neel Syndrome Accompanying Waldenström's Macroglobulinemia with R-MPV: A Case ReportYoshitaka Kikukawa, Ayako Yamamura-Fujimoto, Shinya Endo, et al.
Pageof 7